The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...

Despite numerous therapeutic research efforts, treatment of BV remains cumbersome and clinicians are currently rather poorly armed to treat BV properly in the long run. Moreover, appraisal of the ...

Bacterial vaginosis is confined to an asymptomatic state in at least half of the cases. Symptomatic BV, on the other hand, is most typically accompanied by foul-smelling, profuse vaginal discharge ...

SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financial results for the third quarter and ...

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended ...

Improved loss from operations by 31% - - Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health ...

Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

Daré Bioscience, Inc. ( NASDAQ: DARE) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

A woman said she visited her GP 12 times before eventually being diagnosed with a rare type of tumour. Nikki Helme, 35, from ...

Brian Kemp Dolliver; Analyst; Brookline Capital Markets Douglas Tsao; Analyst; H.C. Wainwright & Co LLC ...

Post-election, leaders from Cadence OTC, Evvy, Flora Fertility, G2G Consulting, and Winx Health share their summary of and ...